This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
EDAP TMS (EDAP) Catches Eye: Stock Jumps 7.4%
by Zacks Equity Research
EDAP TMS (EDAP) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
5 Top-Ranked Stocks Poised to Beat on Q2 Earnings This Week
by Nalak Das
We have narrowed down our search to five Zacks Rank #1 stocks slated to release earrings results this week with a positive Earnings ESP.
Testing Volume to Aid Quest Diagnostics' (DGX) Q2 Earnings?
by Zacks Equity Research
Looking at this demand for testing, Quest Diagnostics (DGX) has significantly picked up capacity to perform molecular diagnostic tests a day.
What's in Store for West Pharmaceutical's (WST) Q2 Earnings?
by Zacks Equity Research
West Pharmaceutical Services (WST) is likely to have gained from continued strength in high-value product sales in Q2.
What's in the Cards for Intuitive Surgical (ISRG) Q2 Earnings?
by Zacks Equity Research
Intuitive Surgical's (ISRG) second-quarter earnings are likely to reflect weaker-than-expected performance at Instruments & Accessories segment and decline in da Vince procedure volume.
Top Ranked Momentum Stocks to Buy for July 17th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, July 17th
3 Inexpensive MedTech Gainers of 2H20 Beyond TMO and RMD
by Zacks Equity Research
Here we look at three cheap MedTech stocks that investors can take a look at apart from giants like Thermo Fisher and ResMed that are expensive.
Luminex (LMNX) Catches Eye: Stock Jumps 7.1%
by Zacks Equity Research
Luminex (LMNX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
What's in Store for Edwards Lifesciences (EW) in Q2 Earnings?
by Zacks Equity Research
Robust customer adoption of the TruWave disposable pressure monitoring devices and INSPIRIS RESILIA aortic valve are likely to have driven Edwards Lifesciences' (EW) Q2 revenues.
Soliton (SOLY) Looks Good: Stock Adds 6.5% in Session
by Zacks Equity Research
Soliton (SOLY) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Thermo Fisher Scientific (TMO) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Thermo Fisher (TMO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Align Technology (ALGN) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Align Technology (ALGN) is expected to have gained from continued strength in Clear Aligner shipment volumes in Q2.
Thermo Fisher (TMO) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
The rest of businesses within Life-Science Solutions segment of Thermo Fisher (TMO) are likely to have registered strong quarterly growth led by genetic sciences and bio production businesses.
OrganiGram (OGI) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
OrganiGram (OGI) is expected to have benefited from its focus on building brand equity and product launches in the fiscal third quarter despite pandemic-hit business conditions.
Turtle Beach, Eventbrite, Thermo Fisher Scientific, UBS Group and Canadian Pacific Railway highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Turtle Beach, Eventbrite, Thermo Fisher Scientific, UBS Group and Canadian Pacific Railway highlighted as Zacks Bull and Bear of the Day
Medical Instruments Outlook Dull Amid Coronavirus Crisis
by Urmimala Biswas
Many sub domains within the medical instrument space are bearing the brunt of the coronavirus-led prolonged stay-at-home orders.
Time to Study Earnings: Global Week Ahead
by John Blank
"Bottoms-up" consensus expects earnings per share (EPS) to average $25.60 across Q2, down -6% from Q1, and close to a -40% drop in y/y terms. Guidance--if provided--becomes critical. So too will survival measures such as cash on hand.
Top Research Reports for Apple, Microsoft & TMobile
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Microsoft (MSFT) and TMobile US (TMUS).
Thermo Fisher Stock Rises on Solid Q2 Growth Expectation
by Zacks Equity Research
Thermo Fisher (TMO) provides encouraging Q2 guidance for organic growth.
Danaher Shares Gain 26% in 3 Months: What's Driving the Rally?
by Zacks Equity Research
Danaher (DHR), with 26% growth in shares in the past three months, benefits from healthy demand for its products and synergistic benefits from acquired assets despite the pandemic-led woes.
Pharmaceutical Wholesale to Aid Walgreens' (WBA) Q3 Earnings?
by Zacks Equity Research
Walgreen Boots' (WBA) international businesses in the third quarter is likely to have suffered a huge blow with international trade coming almost to a standstill.
Why Thermo Fisher (TMO) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Thermo Fisher (TMO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
The Zacks Analyst Blog Highlights: Facebook, Thermo Fisher Scientific, McDonalds, NIKE and QUALCOMM
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Facebook, Thermo Fisher Scientific, McDonalds, NIKE and QUALCOMM
3 AI Healthcare Stocks to Ride Out the Coronavirus Resurgence
by Manaswita Ghosh Dutta
Efficient use of data by artificially intelligent applications has put into the spotlight their urgent need in the healthcare domain.
QIAGEN's (QGEN) Selloff Deal With Thermo Fisher Progresses
by Zacks Equity Research
QIAGEN's (QGEN) acquisition deal with Thermo Fisher receives approval from QIAGEN shareholders.